|
US1706096A
(en)
|
1924-01-28 |
1929-03-19 |
Monogram Lens Corp |
Lamp focusing apparatus
|
|
US4401756A
(en)
|
1981-04-14 |
1983-08-30 |
Immunex Corporation |
Process for preparing human interleukin 2
|
|
US4593002A
(en)
|
1982-01-11 |
1986-06-03 |
Salk Institute Biotechnology/Industrial Associates, Inc. |
Viruses with recombinant surface proteins
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US7198919B1
(en)
|
1983-04-25 |
2007-04-03 |
Genentech, Inc. |
Use of alpha factor sequences in yeast expression systems
|
|
US4512584A
(en)
|
1983-06-24 |
1985-04-23 |
Western Publishing Company, Inc. |
Improved game board with pieces cooperating for rotation
|
|
US4604377A
(en)
|
1984-03-28 |
1986-08-05 |
Cetus Corporation |
Pharmaceutical compositions of microbially produced interleukin-2
|
|
DE3583880D1
(de)
|
1984-04-09 |
1991-10-02 |
Takeda Chemical Industries Ltd |
Stabile interleukin-2-zusammensetzung.
|
|
US4569794A
(en)
|
1984-12-05 |
1986-02-11 |
Eli Lilly And Company |
Process for purifying proteins and compounds useful in such process
|
|
US4752585A
(en)
|
1985-12-17 |
1988-06-21 |
Cetus Corporation |
Oxidation-resistant muteins
|
|
US5116943A
(en)
|
1985-01-18 |
1992-05-26 |
Cetus Corporation |
Oxidation-resistant muteins of Il-2 and other protein
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
DE3676670D1
(de)
*
|
1985-06-26 |
1991-02-07 |
Cetus Corp |
Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4931544A
(en)
|
1986-09-04 |
1990-06-05 |
Cetus Corporation |
Succinylated interleukin-2 for pharmaceutical compositions
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US5126132A
(en)
|
1989-08-21 |
1992-06-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Tumor infiltrating lymphocytes as a treatment modality for human cancer
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
WO1991010737A1
(en)
|
1990-01-11 |
1991-07-25 |
Molecular Affinities Corporation |
Production of antibodies using gene libraries
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US6916605B1
(en)
|
1990-07-10 |
2005-07-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
CA2405246A1
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with alterred binding properties
|
|
JPH06509578A
(ja)
|
1991-07-26 |
1994-10-27 |
ユニバーシティ・オブ・ロチェスター |
悪性細胞利用による癌治療法
|
|
US5283185A
(en)
|
1991-08-28 |
1994-02-01 |
University Of Tennessee Research Corporation |
Method for delivering nucleic acids into cells
|
|
US5858784A
(en)
|
1991-12-17 |
1999-01-12 |
The Regents Of The University Of California |
Expression of cloned genes in the lung by aerosol- and liposome-based delivery
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
US5320663A
(en)
|
1992-07-02 |
1994-06-14 |
E. I. Du Pont De Nemours And Company |
Method of obtaining lead and organolead from contaminated media using metal accumulating plants
|
|
US5334761A
(en)
|
1992-08-28 |
1994-08-02 |
Life Technologies, Inc. |
Cationic lipids
|
|
WO1995002698A1
(en)
|
1993-07-12 |
1995-01-26 |
Life Technologies, Inc. |
Composition and methods for transfecting eukaryotic cells
|
|
US5631236A
(en)
|
1993-08-26 |
1997-05-20 |
Baylor College Of Medicine |
Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
|
|
US5698443A
(en)
|
1995-06-27 |
1997-12-16 |
Calydon, Inc. |
Tissue specific viral vectors
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US5650234A
(en)
|
1994-09-09 |
1997-07-22 |
Surface Engineering Technologies, Division Of Innerdyne, Inc. |
Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6696248B1
(en)
|
1995-08-18 |
2004-02-24 |
Morphosys Ag |
Protein/(poly)peptide libraries
|
|
JP4793971B2
(ja)
|
1999-08-09 |
2011-10-12 |
メルク パテント ゲーエムベーハー |
複合サイトカイン−抗体複合体
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
CA2406864A1
(en)
|
2000-02-24 |
2001-08-30 |
Life Technologies Corporation |
Simultaneous stimulation and concentration of cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US20040259247A1
(en)
|
2000-12-01 |
2004-12-23 |
Thomas Tuschl |
Rna interference mediating small rna molecules
|
|
US7371371B2
(en)
|
2001-08-13 |
2008-05-13 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US20080017377A1
(en)
|
2006-07-19 |
2008-01-24 |
Cowan Kenneth M |
Well fluid formulation and method
|
|
US20100041872A1
(en)
*
|
2006-10-04 |
2010-02-18 |
Defrees Shawn |
Glycerol linked pegylated sugars and glycopeptides
|
|
FR2906808B1
(fr)
|
2006-10-10 |
2012-10-05 |
Univ Nantes |
Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
|
|
US10155038B2
(en)
|
2007-02-02 |
2018-12-18 |
Yale University |
Cells prepared by transient transfection and methods of use thereof
|
|
EP2406284B9
(en)
|
2009-03-10 |
2017-03-01 |
Biogen MA Inc. |
Anti-bcma antibodies
|
|
DK3323830T3
(da)
|
2010-06-19 |
2023-09-25 |
Memorial Sloan Kettering Cancer Center |
Anti-gd2 antibodies
|
|
EP3467101A3
(en)
|
2010-09-08 |
2019-06-19 |
Baylor College of Medicine |
Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells
|
|
US8289050B2
(en)
|
2010-09-21 |
2012-10-16 |
Micron Technology, Inc. |
Switching circuits, latches and methods
|
|
ES2866674T3
(es)
|
2010-11-12 |
2021-10-19 |
Nektar Therapeutics |
Conjugados de una fracción de IL-2 y un polímero
|
|
HUE029139T2
(hu)
|
2011-02-10 |
2017-02-28 |
Roche Glycart Ag |
Mutáns interleukin-2 polipeptidek
|
|
WO2012119093A1
(en)
*
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
KR101815323B1
(ko)
|
2011-09-08 |
2018-01-05 |
삼성전자주식회사 |
복수의 무선 전력 수신기로부터 무선 전력 공급기에 신호를 송신하는 방법 및 장치
|
|
EP3692794A1
(en)
|
2011-09-16 |
2020-08-12 |
Baylor College of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
|
ITMO20110270A1
(it)
|
2011-10-25 |
2013-04-26 |
Sara Caldrer |
Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
US9439768B2
(en)
|
2011-12-08 |
2016-09-13 |
Imds Llc |
Glenoid vault fixation
|
|
JP6850528B2
(ja)
|
2012-02-13 |
2021-03-31 |
シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート |
二重特異性キメラ抗原受容体およびその治療的使用
|
|
KR102437522B1
(ko)
|
2012-05-25 |
2022-08-26 |
셀렉티스 |
면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
|
|
WO2013192294A1
(en)
|
2012-06-20 |
2013-12-27 |
Boston 3T Biotechnologies, Inc. |
Cellular therapies for treating and preventing cancers and other immune system disorders
|
|
CN104140974B
(zh)
*
|
2013-05-08 |
2017-09-29 |
科济生物医药（上海）有限公司 |
编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
|
|
GB201405845D0
(en)
*
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
US20150315566A1
(en)
|
2014-04-30 |
2015-11-05 |
The Board Of Trustees Of The University Of Illinois |
Method for generating high affinity, bivalent binding agents
|
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
|
|
WO2016025385A1
(en)
|
2014-08-11 |
2016-02-18 |
Delinia, Inc. |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
WO2016115168A1
(en)
|
2015-01-12 |
2016-07-21 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
|
EP3256492A4
(en)
*
|
2015-02-09 |
2018-07-11 |
University of Florida Research Foundation, Inc. |
Bi-specific chimeric antigen receptor and uses thereof
|
|
ES2857998T3
(es)
*
|
2015-02-12 |
2021-09-29 |
Univ Health Network |
Receptores de antígenos quiméricos
|
|
KR102011789B1
(ko)
*
|
2015-08-05 |
2019-08-19 |
주식회사 셀랩메드 |
키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포
|
|
WO2017027422A1
(en)
|
2015-08-07 |
2017-02-16 |
Alexo Therapeutics Inc. |
Constructs having a sirp-alpha domain or variant thereof
|
|
CN106467906B
(zh)
*
|
2015-08-20 |
2019-09-27 |
北京马力喏生物科技有限公司 |
构建体、转基因淋巴细胞及其制备方法和用途
|
|
KR102739782B1
(ko)
*
|
2015-09-11 |
2024-12-09 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
생물학적으로 관련된 직교 사이토카인/수용체 쌍
|
|
CN105331585A
(zh)
|
2015-11-13 |
2016-02-17 |
科济生物医药（上海）有限公司 |
携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
|
|
MX2019004707A
(es)
|
2016-10-26 |
2019-08-12 |
Iovance Biotherapeutics Inc |
Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
|
|
EP4043485A1
(en)
*
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
WO2019028419A1
(en)
|
2017-08-03 |
2019-02-07 |
Synthorx, Inc. |
CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
|
|
CN109554348A
(zh)
*
|
2017-09-27 |
2019-04-02 |
亘喜生物科技（上海）有限公司 |
可诱导分泌抗cd47抗体的工程化免疫细胞
|
|
KR20200075851A
(ko)
|
2017-10-19 |
2020-06-26 |
셀렉티스 |
개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합
|
|
US20200299349A1
(en)
|
2017-11-21 |
2020-09-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Partial agonists of interleukin-2
|
|
WO2019169290A1
(en)
*
|
2018-03-02 |
2019-09-06 |
Allogene Therapeutics, Inc. |
Inducible chimeric cytokine receptors
|
|
CN108728460A
(zh)
*
|
2018-05-25 |
2018-11-02 |
上海恒润达生生物科技有限公司 |
靶向gd2的嵌合抗原受体及其用途
|
|
WO2019237035A1
(en)
*
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
EP3847197A1
(en)
*
|
2018-09-05 |
2021-07-14 |
Poseida Therapeutics, Inc. |
Allogeneic cell compositions and methods of use
|